ERBB2 and breast cancer: Treatment of athymic mice with subcutaneous (s.c.)HER2-positive MDA-MB-361 human BC xenografts with a single amount of 111In[In]-DTPA-trastuzumab-NLS (9.25 MBq; 4 mg/kg) administered by i.p. injection inhibited tumour growth by fourfold compared to untreated mice and did not cause any normal tissue toxicity, including to the hematopoietic system (Costantini et al. 2010a).